

DUR Committee  
April 15, 2011 Minutes

**Members Present**

Robert Carlson, M.D.

William McCormick, Pharm.D. (telephonic)

John Pappenheim, M.D.

Dharna Begich, Pharm.D.

Mary-Beth Gardner, ANP

Jeff Demain, M.D.

Chad Hope, Pharm.D. (DHSS)

Julie Pritchard, Pharm.D. (Magellan)

Dave Campana, R.Ph (DHSS Pharmacy Program Manager)

- Two new members were welcomed to the committee (Mary-Beth Gardner and Jeff Demain)
- An update to the by-laws was discussed after 10 day advance notice was provided to the committee members. Following the discussion the committee voted unanimously to amend the by-laws to require interventions to be approved by a simple majority of members present with at least one pharmacist and one physician voting to approve the initiative and the ex officio member of the committee cannot be the sole vote in favor of the initiative for their profession.
- Bactroban cream utilization data was presented by Chad Hope and criteria for prior authorization was discussed. Following discussion the committee voted unanimously to place Bactroban cream on prior authorization.
- Chad Hope presented FDA approved indications for botulinum toxin products to the committee and discussed the potential for misuse of these products. Following lengthy discussion regarding the prior authorization criteria the committee voted unanimously to place all botulinum toxin products (Botox, Myobloc and Dysport) on prior authorization.
- The retrospective profile reviews focused on polypharmacy and overutilization.
- The meeting adjourned at 3:15p.m.